Ivor Campbell looks at the way the UK medtech sector has responded to COVID-19 and the implications of more advanced diagnostics for prescribing and general practice.
A bumper crop of orphan drugs from the likes of Amicus, Kyowa Kirin, Eusa and Biogen dominates this year’s UK Prix Galien shortlist as biotech firms and specialist pharma companies cement t
Overview
The rise of mobile devices and apps, not to mention the involvement of non-medical technology players, is creating a wave of irrevocable digital change for medtech.
